The start of the 21st century has produced advances in cancer care that have improved both survival rates and quality of life for many persons diagnosed with cancer. Targeted therapy has given new hope for controlling cancer as a chronic illness. Alone, or in combination with traditional therapies such as surgery, radiation, and/or chemotherapy, this new form of therapy targets malignant cells, halting tumor growth and the potential metastatic spread of disease. Toxicities are limited, but some are serious and may require intensive care. It is imperative for the experienced critical care nurse to have an understanding of these new treatment options and those on the horizon, as these therapies are the future of cancer care. Whereas in previous decades, patients with cancer may not have survived an intensive care admission for treatment complications or advanced disease, many patients now are recovering from life-threatening events, continuing treatment for their disease, and going on to live meaningful, good-quality lives.
Skip Nav Destination
Article navigation
1 October 2011
Symposium Current Care and Perspectives of the Critically Ill Cancer Patient|
October 01 2011
Advances in Oncology Care: Targeted Therapies
Kristi Beatty, RN, MSN;
Kristi Beatty, RN, MSN
Kristi Beatty is Clinical Trials Nurse, University Hospitals Seidman Cancer Center, Wearn 552, 11100 Euclid Ave, Cleveland, OH 44106 ([email protected]). Chris Winkelman is Associate Professor, Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio. Joseph A. Bokar is Assistant Professor, University Hospitals Seidman Cancer Center, Cleveland, Ohio. Polly Mazanec is Assistant Professor, Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio.
Search for other works by this author on:
Chris Winkelman, RN, PhD, ACNP;
Chris Winkelman, RN, PhD, ACNP
Kristi Beatty is Clinical Trials Nurse, University Hospitals Seidman Cancer Center, Wearn 552, 11100 Euclid Ave, Cleveland, OH 44106 ([email protected]). Chris Winkelman is Associate Professor, Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio. Joseph A. Bokar is Assistant Professor, University Hospitals Seidman Cancer Center, Cleveland, Ohio. Polly Mazanec is Assistant Professor, Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio.
Search for other works by this author on:
Joseph A. Bokar, MD, PhD;
Joseph A. Bokar, MD, PhD
Kristi Beatty is Clinical Trials Nurse, University Hospitals Seidman Cancer Center, Wearn 552, 11100 Euclid Ave, Cleveland, OH 44106 ([email protected]). Chris Winkelman is Associate Professor, Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio. Joseph A. Bokar is Assistant Professor, University Hospitals Seidman Cancer Center, Cleveland, Ohio. Polly Mazanec is Assistant Professor, Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio.
Search for other works by this author on:
Polly Mazanec, PhD, ACNP-BC, AOCN
Polly Mazanec, PhD, ACNP-BC, AOCN
Kristi Beatty is Clinical Trials Nurse, University Hospitals Seidman Cancer Center, Wearn 552, 11100 Euclid Ave, Cleveland, OH 44106 ([email protected]). Chris Winkelman is Associate Professor, Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio. Joseph A. Bokar is Assistant Professor, University Hospitals Seidman Cancer Center, Cleveland, Ohio. Polly Mazanec is Assistant Professor, Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio.
Search for other works by this author on:
AACN Adv Crit Care (2011) 22 (4): 323–334.
Citation
Kristi Beatty, Chris Winkelman, Joseph A. Bokar, Polly Mazanec; Advances in Oncology Care: Targeted Therapies. AACN Adv Crit Care 1 October 2011; 22 (4): 323–334. doi: https://doi.org/10.4037/NCI.0b013e3182310178
Download citation file:
Sign in
Don't already have an account? Register
Short-term Access
Purchase short-term access on a pay-per-article or pay-per-issue basis.
$15 72 - hour single article access $30 7 - day full issue access